Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Canakinumab||Ilaris||ACZ-885||Ilaris (canakinumab) is a monoclonal antibody against interleukin-1beta, which has anti-inflammatory activity and may decrease tumor progression (PMID: 28855077).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04810611||Phase I||NIS793 Sabatolimab Canakinumab + Sabatolimab NIS793 + Sabatolimab Canakinumab||Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS||Active, not recruiting||USA | ITA | ESP | AUS||4|
|NCT03447769||Phase III||Canakinumab||Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None)||Terminated||USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT||33|
|NCT05467800||Phase II||Canakinumab||Study of Canakinumab in Patients With Myelofibrosis||Recruiting||USA||0|
|NCT03968419||Phase II||Canakinumab Pembrolizumab Canakinumab + Pembrolizumab||This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)||Terminated||USA | FRA | ESP | DEU | CAN | BEL||6|
|NCT02900664||Phase I||Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab||A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)||Completed||USA | ITA | FRA | ESP | CAN | BEL||3|